"Pharmacological Study of Bufadene Total Lactones and Related Marketed Preparations Against Novel Coronavirus 2019-nCoV"

　　In December 2019, a new type of coronavirus (2019 Novel Coronavirus, 2019-nCoV) infection appeared in Wuhan City, Hubei Province. Similar cases. At present, the National Health Commission has received reports from 31 provinces (autonomous regions, municipalities directly under the central government) and the Xinjiang Production and Construction Corps, with a total of more than 80,000 confirmed cases and more than 3,000 deaths, with a case fatality rate of about 3.7%. There is still no specific treatment for the novel coronavirus pneumonia. Early diagnosis and timely development of specific drugs are the key to preventing the spread of the epidemic. On February 18, 2020, the Guangdong provincial government held a regular press conference on epidemic prevention and control. Zhong Nanshan, an academician of the Chinese Academy of Engineering, attended the conference and reported the latest progress in drug research for the treatment of new coronaviruses. Academician Zhong Nanshan said that there is a process for Western medicine to enter the human body, but Chinese medicine is different. In this anti-epidemic process, the first batch of traditional Chinese medicines used include Liushen Pills, Lianhua Qingwen Capsules, Jinzhen Oral Liquid, Reduning Injection, etc. These traditional Chinese medicines have been used in general clinical practice for many years.

　　Hefei Huafang Pharmaceutical Technology Co., Ltd. actively responded to the call of the Hefei Municipal Government to fight against the "new coronavirus pneumonia epidemic". The idea is to explore and develop the application of total bufasterene lactones and related marketed preparations in anti-new coronavirus.

　　On the basis of the 2018 national major new drug development project - "Research on the new anti-tumor component new drug bufastenolactone and its osmotic pump controlled-release tablets", the team found that bufastenolactone has a significant anti-tumor effect. Viral activity; Chansu Injection has significant clinical efficacy in the treatment of human viral pneumonia and other respiratory tract infection diseases. Therefore, the scientific and technological research of the "Pharmacological Research on the Total Bufastenolactones and Related Marketed Preparations Against the Novel Coronavirus 2019-nCoV" project was launched urgently. Among the effector groups and existing marketed drugs such as Chansu Injection and Cinobufacin Oral Liquid, look for innovative drugs that can be applied to fight against the new coronavirus 2019-nCoV.

　　At present, 12 kinds of monomeric compounds have been isolated from the bufadenolactone effector group, including a new monomer compound, which lays the foundation for the preclinical pharmacodynamic evaluation and safety evaluation of the bufadenolactone effector group in the later stage of anti-new coronavirus. working basis.

　　At present, the first round of toxicity screening has been completed, and the second round of research and screening of pharmacodynamic activity screening and immunomodulatory activity on influenza virus models is being carried out. In the near future, the establishment of the new coronavirus 2019-nCoV model and the third round of screening of the anti-new coronavirus 2019-nCoV pharmacodynamics research will be completed, and the evaluation of the inhibitory effect of total lactones and related marketed preparations on the new coronavirus will be completed at the cell level, and the anti-new coronavirus pneumonia will be developed. To promote these drugs to pass the safety and effectiveness evaluation as soon as possible, realize clinical transformation application, and provide a new clinical treatment plan for the prevention and treatment of new coronavirus infection or similar viral diseases.

　　At present, the researchers are planning to conduct the third round of screening of new coronavirus 2019-nCoV model establishment and anti-new coronavirus 2019-nCoV pharmacodynamics research, to complete the evaluation of the inhibitory effect of total lactones and related marketed preparations on the new coronavirus at the cell level, and to develop Potential drugs against COVID-19.